Literature DB >> 15732857

Effect of alendronate on periodontal disease in postmenopausal women: a randomized placebo-controlled trial.

Miriam L Rocha1, Juan M Malacara, Francisco J Sánchez-Marin, Carlos J Vazquez de la Torre, Martha E Fajardo.   

Abstract

BACKGROUND: We investigated the effect of oral alendronate (ALN) treatment on radiological and clinical measurements of periodontal disease in postmenopausal women without hormone replacement therapy.
METHODS: We evaluated the effect of 6 months of ALN treatment in 40 postmenopausal women, 55 to 65 years old with established periodontal disease, in a controlled, double-masked, prospective study. Volunteers were paired by age and randomized to receive ALN (10 mg/day) or placebo for the study period. Periodontal mechanical treatment was carried out in both groups. At baseline and after treatment, clinical evaluation, hormone blood levels, distance from the crestal alveolar bone (CAB) to the cemento-enamel junction (CEJ), calcaneus bone mineral density (BMD), hormone levels, serum N-telopeptide (NTx), and bone-specific alkaline phosphatase (BSAP) were assessed.
RESULTS: Periodontal disease conditions improved in both groups, but greater improvement in probing depth (-0.8 +/- 0.3 mm versus -0.4 +/- 0.4 mm, P = 0.02) and gingival bleeding (-0.3% +/- 0.13% versus -0.2% +/- 0.06%, P = 0.006) was found in the ALN treated group. Calcaneus BMD increased in the ALN treated group (68 +/- 47 mm3 versus -26 +/- 81 mm3, P = 0.0006). CAB-CEJ distance diminished in the ALN group (-0.4 +/- 0.40 mm versus 0.60 +/- 0.53 mm, P = 0.00008). Marginal reduction in both NTx and BSAP levels was found in the ALN group (-9.4 +/- 6.6 nmol versus -4.3 +/- 4.7 nmol bone collagen equivalents, P = 0.08, and -7.7 +/- 8.4 versus -1.5 +/- 5.0 U/l, P = 0.1, respectively). Hormone levels were unchanged after treatment. Similar improvement of calcaneus BMD and CAB-CEJ distance with ALN treatment was found in obese and non-obese women.
CONCLUSION: ALN treatment improved periodontal disease and bone turnover in postmenopausal women.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15732857     DOI: 10.1902/jop.2004.75.12.1579

Source DB:  PubMed          Journal:  J Periodontol        ISSN: 0022-3492            Impact factor:   6.993


  22 in total

Review 1.  Novel host response therapeutic approaches to treat periodontal diseases.

Authors:  Keith L Kirkwood; Joni A Cirelli; Jill E Rogers; William V Giannobile
Journal:  Periodontol 2000       Date:  2007       Impact factor: 7.589

2.  Association of osteoporosis and bone medication with the periodontal condition in elderly women.

Authors:  D C Penoni; S R Torres; M L F Farias; T M Fernandes; R R Luiz; A T T Leão
Journal:  Osteoporos Int       Date:  2015-12-01       Impact factor: 4.507

3.  Teriparatide and osseous regeneration in the oral cavity.

Authors:  Jill D Bashutski; Robert M Eber; Janet S Kinney; Erika Benavides; Samopriyo Maitra; Thomas M Braun; William V Giannobile; Laurie K McCauley
Journal:  N Engl J Med       Date:  2010-10-16       Impact factor: 91.245

Review 4.  Efficacy of bisphosphonate as an adjunct to nonsurgical periodontal therapy in the management of periodontal disease: a systematic review.

Authors:  Zohaib Akram; Tariq Abduljabbar; Sergio Varela Kellesarian; Mohamed Ibrahim Abu Hassan; Fawad Javed; Fahim Vohra
Journal:  Br J Clin Pharmacol       Date:  2016-11-10       Impact factor: 4.335

5.  Femur bone repair in ovariectomized rats under the local action of alendronate, hydroxyapatite and the association of alendronate and hydroxyapatite.

Authors:  Antonio Carlos Victor Canettieri; Carlos Eduardo Dias Colombo; Chung Man Chin; Horácio Faig-Leite
Journal:  Int J Exp Pathol       Date:  2009-10       Impact factor: 1.925

6.  Osteoporosis/osteopenia as an independent factor associated with periodontitis in postmenopausal women: a case-control study.

Authors:  J S Passos; M I P Vianna; I S Gomes-Filho; S S Cruz; M L Barreto; L Adan; C K Rösing; E M M Cerqueira; S C Trindade; J M F Coelho
Journal:  Osteoporos Int       Date:  2012-09-22       Impact factor: 4.507

7.  Periodontal health in breast cancer patients on aromatase inhibitors versus postmenopausal controls: a longitudinal analysis.

Authors:  Iwonka Eagle; Erika Benavides; Robert Eber; Giselle Kolenic; Younghun Jung; Catherine Van Poznak; L Susan Taichman
Journal:  J Clin Periodontol       Date:  2016-05-19       Impact factor: 8.728

8.  Clinical and radiographic evaluation of effect of risedronate 5 mg as an adjunct to treatment of chronic periodontitis in postmenopausal women (12-month study).

Authors:  N V Bhavsar; S R Trivedi; K Dulani; N Brahmbhatt; S Shah; D Chaudhri
Journal:  Osteoporos Int       Date:  2016-03-30       Impact factor: 4.507

Review 9.  Non-surgical chemotherapeutic treatment strategies for the management of periodontal diseases.

Authors:  Joe W Krayer; Renata S Leite; Keith L Kirkwood
Journal:  Dent Clin North Am       Date:  2010-01

10.  Periodontal disease as a risk factor for bisphosphonate-related osteonecrosis of the jaw.

Authors:  Vivek Thumbigere-Math; Bryan S Michalowicz; James S Hodges; Michaela L Tsai; Karen K Swenson; Laura Rockwell; Rajaram Gopalakrishnan
Journal:  J Periodontol       Date:  2013-06-20       Impact factor: 6.993

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.